Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity
| dc.contributor.author | Kraker, Raymond T. | |
| dc.contributor.author | Wallace, David K. | |
| dc.contributor.author | Beck, Roy W. | |
| dc.contributor.author | Saunders, Christina T. | |
| dc.contributor.author | Lorenzi, Elizabeth | |
| dc.contributor.author | Melia, B. Michele | |
| dc.contributor.author | Li, Zhuokai | |
| dc.contributor.department | Ophthalmology, School of Medicine | |
| dc.date.accessioned | 2024-04-04T08:05:30Z | |
| dc.date.available | 2024-04-04T08:05:30Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | This study determines which of 8 doses of bevacizumab are effective in treating severe retinopathy of prematurity to carry forward to a large-scale randomized clinical trial. | |
| dc.identifier.citation | Kraker RT, Wallace DK, Beck RW, et al. Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity. JAMA Ophthalmol. 2021;139(10):1143-1144. doi:10.1001/jamaophthalmol.2021.3192 | |
| dc.identifier.uri | https://hdl.handle.net/1805/39741 | |
| dc.language.iso | en_US | |
| dc.publisher | American Medical Association | |
| dc.relation.isversionof | 10.1001/jamaophthalmol.2021.3192 | |
| dc.relation.journal | JAMA Ophthalmology | |
| dc.rights | Publisher Policy | |
| dc.source | PMC | |
| dc.subject | Angiogenesis inhibitors | |
| dc.subject | Bevacizumab | |
| dc.subject | Intravitreal injections | |
| dc.subject | Laser coagulation | |
| dc.subject | Retinopathy of prematurity | |
| dc.title | Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity | |
| dc.type | Article | |
| ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377606/ |